Key result
The authors agree that further research on the efficacy and safety of sNinj1 mimetic peptides in other organs is needed before clinical translation for atherosclerosis.
Further research is required to establish the safety and efficacy of sNinj1 mimetic peptides for atherosclerosis treatment.
including bone marrow, blood, spleen, lymph nodes, etc) during atherosclerosis.We suggest that using synthetic mimetic might be a viable strategy for biological therapies, but further research is needed to validate the potency of them as agents.Thus, we fully agree with the comment by Drs Yang, Zheng, and their colleagues that further research for efficacy and safety in other organs is needed to clinically translate the sNinj1 mimetic peptides to be useful therapies for atherosclerosis.
No takes yet. Share an insight, caveat, or question.
Jeon et al. (2021) conducted a letter in Atherosclerosis. sNinj1 mimetic peptides was evaluated. The authors agree that further research on the efficacy and safety of sNinj1 mimetic peptides in other organs is needed before clinical translation for atherosclerosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: